CancerDrs

Breast Cancer clinical trials in New Hampshire

9 actively recruiting breast cancer trials at 4 sites across New Hampshire.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in New Hampshire:
  • New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center — Lebanon, New Hampshire
  • Solinsky Center for Cancer Care — Manchester, New Hampshire
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in New Hampshire:
  • New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center — Lebanon, New Hampshire
  • Solinsky Center for Cancer Care — Manchester, New Hampshire
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to der…

Sponsor: American Society of Clinical Oncology
NCT ID: NCT06377852
Sites in New Hampshire:
  • Dana-Farber/New Hampshire Oncology-Hematology — Londonderry, New Hampshire
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in New Hampshire:
  • Dartmouth Hitchcock Medical — Lebanon, New Hampshire
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.

Sponsor: OncoTherapy Science, Inc.
NCT ID: NCT02926690
Sites in New Hampshire:
  • Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in New Hampshire:
  • New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
  • Solinsky Center for Cancer Care — Manchester, New Hampshire
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation

The goal of this clinical trial is to test the effect of an affect-based exercise prescription on moderate-vigorous physical activity participation among survivors of breast cancer who completed primary treatment within the last 5 years. T…

Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT06258993
Sites in New Hampshire:
  • Dartmouth-Hitchcock Clinic — Lebanon, New Hampshire
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

MRg-NIRS Imaging System Breast Cancer Trial

This trial is a study of 20 women with breast cancer to evaluate the addition of MR-guided (MRg) near-infrared spectroscopy (NIRS) with and without contrast, as part of a program to improve clinical management of women receiving breast mag…

Sponsor: Keith D. Paulsen
NCT ID: NCT06400563
Sites in New Hampshire:
  • Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07